Fibrinolytic Strategy for ST-Segment-Elevation Myocardial Infarction: A Contemporary Review in Context of the COVID-19 Pandemic.
Circ Cardiovasc Interv
; 13(9): e009622, 2020 09.
Article
in English
| MEDLINE | ID: covidwho-744903
ABSTRACT
The ongoing coronavirus disease 2019 pandemic has resulted in additional challenges for systems designed to perform expeditious primary percutaneous coronary intervention for patients presenting with ST-segment-elevation myocardial infarction. There are 2 important considerations the guideline-recommended time goals were difficult to achieve for many patients in high-income countries even before the pandemic, and there is a steep increase in mortality when primary percutaneous coronary intervention cannot be delivered in a timely fashion. Although the use of fibrinolytic therapy has progressively decreased over the last several decades in high-income countries, in circumstances when delays in timely delivery of primary percutaneous coronary intervention are expected, a modern fibrinolytic-based pharmacoinvasive strategy may need to be considered. The purpose of this review is to systematically discuss the contemporary role of an evidence-based fibrinolytic reperfusion strategy as part of a pharmacoinvasive approach, in the context of the emerging coronavirus disease 2019 pandemic.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Fibrinolytic Agents
/
ST Elevation Myocardial Infarction
Type of study:
Reviews
Limits:
Humans
Language:
English
Journal:
Circ Cardiovasc Interv
Journal subject:
Vascular Diseases
/
Cardiology
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS